Research graph

References

References from KRAS G12C Inhibition Remodels the Non-Small Cell Lung Cancer Surfaceome to Uncover Targetable Vulnerabilities. Local targets link to admitted publications; unresolved targets remain external evidence.

10.1016/j.jtho.2026.103695

10.1016/j.jtho.2026.103695 · External reference

10.1056/nejmoa2103695

10.1056/nejmoa2103695 · External reference

10.1056/nejmoa2204619

10.1056/nejmoa2204619 · External reference

10.1016/s0140-6736(23)00221-0

10.1016/s0140-6736(23)00221-0 · External reference

10.1158/2159-8290.cd-21-0365

10.1158/2159-8290.cd-21-0365 · External reference

10.1038/s41586-021-04065-2

10.1038/s41586-021-04065-2 · External reference

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors

10.1016/j.annonc.2025.01.020 · 2025 · External reference

10.1056/nejmoa2105281

10.1056/nejmoa2105281 · External reference

10.1016/j.ccell.2024.01.012

10.1016/j.ccell.2024.01.012 · External reference

10.1158/2159-8290.cd-23-0289

10.1158/2159-8290.cd-23-0289 · External reference

10.1158/2159-8290.cd-24-0421

10.1158/2159-8290.cd-24-0421 · External reference

10.1056/nejmoa1801005

10.1056/nejmoa1801005 · External reference

10.1056/nejmoa1606774

10.1056/nejmoa1606774 · External reference

10.1200/jco.2024.42.16_suppl.8512

10.1200/jco.2024.42.16_suppl.8512 · External reference

10.1016/j.jtho.2025.11.018

10.1016/j.jtho.2025.11.018 · External reference

Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+advanced non-small cell lung cancer (NSCLC)

10.1200/jco.2024.42.16_suppl.tps8651 · 2024 · External reference

10.1158/2159-8290.cd-24-0708

10.1158/2159-8290.cd-24-0708 · External reference

10.7554/elife.31098

10.7554/elife.31098 · External reference

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

10.1016/j.ccell.2023.01.007 · 2023 · External reference

Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy

10.1016/j.xcrm.2025.102513 · 2025 · External reference

10.1016/j.tem.2021.12.003

10.1016/j.tem.2021.12.003 · External reference

10.1016/j.ygyno.2007.11.020

10.1016/j.ygyno.2007.11.020 · External reference

Exploiting the folate receptor α in oncology

10.1038/s41571-020-0339-5 · 2020 · External reference

10.1016/j.ab.2004.12.026

10.1016/j.ab.2004.12.026 · External reference

10.1158/1535-7163.mct-14-1095

10.1158/1535-7163.mct-14-1095 · External reference

10.1200/jco.22.01900

10.1200/jco.22.01900 · External reference

10.1016/j.annonc.2021.02.017

10.1016/j.annonc.2021.02.017 · External reference

10.1016/j.neo.2016.11.002

10.1016/j.neo.2016.11.002 · External reference

Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers

10.1158/1078-0432.ccr-25-1749 · 2025 · External reference

Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort

10.1200/jco.2023.41.16_suppl.5508 · 2023 · External reference

10.1158/1535-7163.mct-24-0649

10.1158/1535-7163.mct-24-0649 · External reference

10.1158/1078-0432.ccr-20-4740

10.1158/1078-0432.ccr-20-4740 · External reference

10.1158/2159-8290.cd-22-0158

10.1158/2159-8290.cd-22-0158 · External reference

10.1038/s41591-026-04537-w

10.1038/s41591-026-04537-w · External reference

10.1038/s41586-022-04928-2

10.1038/s41586-022-04928-2 · External reference

10.1126/science.ads0239

10.1126/science.ads0239 · External reference

10.1126/science.adk0775

10.1126/science.adk0775 · External reference

10.1093/nar/gku1267

10.1093/nar/gku1267 · External reference

10.1038/s41586-022-05575-3

10.1038/s41586-022-05575-3 · External reference

10.1126/science.adk0850

10.1126/science.adk0850 · External reference

10.1073/pnas.1808790115

10.1073/pnas.1808790115 · External reference

The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets

10.1038/s43018-021-00282-w · 2021 · External reference

10.1126/science.1260419

10.1126/science.1260419 · External reference

10.1126/science.aan2507

10.1126/science.aan2507 · External reference

10.1038/nature13385

10.1038/nature13385 · External reference

10.1016/j.cell.2020.06.013

10.1016/j.cell.2020.06.013 · External reference

10.1097/jto.0b013e31824de09c

10.1097/jto.0b013e31824de09c · External reference

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer

10.1038/s41591-025-03732-5 · 2025 · External reference

10.1111/j.1440-1843.2006.00800.x

10.1111/j.1440-1843.2006.00800.x · External reference

10.1038/s41388-021-02076-x

10.1038/s41388-021-02076-x · External reference

10.1038/s41467-023-44184-0

10.1038/s41467-023-44184-0 · External reference

10.1073/pnas.1906663116

10.1073/pnas.1906663116 · External reference

10.1016/j.celrep.2023.113286

10.1016/j.celrep.2023.113286 · External reference

10.1038/s41586-024-07113-9

10.1038/s41586-024-07113-9 · External reference

10.1042/bsr20170772

10.1042/bsr20170772 · External reference

Folic acid inhibits COLO-205 colon cancer cell proliferation through activating the FRα/c-SRC/ERK1/2/NFκB/TP53 pathway: in vitro and in vivo studies

10.1038/srep11187 · 2015 · External reference

Noncanonical function of folate through folate receptor 1 during neural tube formation

10.1038/s41467-024-45775-1 · 2024 · External reference

10.1242/dev.137315

10.1242/dev.137315 · External reference

10.1242/bio.041160

10.1242/bio.041160 · External reference

Xenopus laevis as a Model Organism for the Study of Spinal Cord Formation, Development, Function and Regeneration

10.3389/fncir.2017.00090 · 2017 · External reference

10.1038/nm.3336

10.1038/nm.3336 · External reference

10.1038/nature06251

10.1038/nature06251 · External reference

10.1101/gad.227413.113

10.1101/gad.227413.113 · External reference

10.1158/0008-5472.can-15-1141

10.1158/0008-5472.can-15-1141 · External reference

10.7554/elife.02313

10.7554/elife.02313 · External reference

10.1083/jcb.201202108

10.1083/jcb.201202108 · External reference

10.1172/jci191370

10.1172/jci191370 · External reference

10.1016/j.stem.2020.07.022

10.1016/j.stem.2020.07.022 · External reference

10.1128/mcb.00323-08

10.1128/mcb.00323-08 · External reference

Epigenetic suppression of E-cadherin expression by Snail2 during the metastasis of colorectal cancer

10.1186/s13148-018-0592-y · 2018 · External reference

Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer

10.1038/s41598-019-57285-y · 2020 · External reference

10.1038/onc.2010.234

10.1038/onc.2010.234 · External reference

10.1158/2159-8290.cd-19-1167

10.1158/2159-8290.cd-19-1167 · External reference

10.3389/fonc.2024.1380584/bibtex

10.3389/fonc.2024.1380584/bibtex · External reference

10.1158/2159-8290.cd-20-0187

10.1158/2159-8290.cd-20-0187 · External reference

10.1126/scisignal.aaw9450

10.1126/scisignal.aaw9450 · External reference

10.1158/2159-8290.cd-22-1420

10.1158/2159-8290.cd-22-1420 · External reference

10.1172/jci155523

10.1172/jci155523 · External reference

10.1126/scitranslmed.aaw7999

10.1126/scitranslmed.aaw7999 · External reference

Folate Receptor α Expression Level Correlates With Histologic Grade in Lung Adenocarcinoma

10.5858/arpa.2015-0431-oa · 2016 · External reference

10.1245/s10434-007-9755-3

10.1245/s10434-007-9755-3 · External reference

10.1038/s41586-019-1694-1

10.1038/s41586-019-1694-1 · External reference

10.1158/1535-7163.mct-20-0462

10.1158/1535-7163.mct-20-0462 · External reference

Antibody drug conjugates: in search of partners of choice

10.1016/j.trecan.2023.01.003 · 2023 · External reference

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer

10.1016/j.ygyno.2025.06.016 · 2025 · External reference

The next generation of antibody–drug conjugates

10.1038/s41591-026-04543-y · 2026 · External reference

Re-evaluating antibody drug conjugate linker stability: assessment, interpretation, and clinical translation

10.1016/j.annonc.2026.04.008 · 2026 · External reference

10.1136/gutjnl-2024-bsg.296

10.1136/gutjnl-2024-bsg.296 · External reference

Role of RAS signaling in ovarian cancer

10.12688/f1000research.126337.1 · 2022 · External reference

Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions

10.1097/cmr.0000000000000258 · 2016 · External reference

Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate

10.1158/1078-0432.ccr-25-2333 · 2025 · External reference

Abstract LB127: A first-in-class bispecific ADC targeting FORL1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model

10.1158/1538-7445.am2024-lb127 · 2024 · External reference

10.1016/j.cell.2014.04.028

10.1016/j.cell.2014.04.028 · External reference

10.1158/2159-8290.cd-24-0177

10.1158/2159-8290.cd-24-0177 · External reference

10.1038/nmeth.1226

10.1038/nmeth.1226 · External reference

10.1093/nar/gkv007

10.1093/nar/gkv007 · External reference

10.1093/bioinformatics/bti270

10.1093/bioinformatics/bti270 · External reference

MaxQuant enables high peptide identification rates, individualized p

2008 · External reference

10.1021/pr101065j

10.1021/pr101065j · External reference

Unresolved reference

External reference

Unresolved reference

External reference

10.1093/database/bau012

10.1093/database/bau012 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

10.1126/scisignal.adu7145

10.1126/scisignal.adu7145 · External reference

Unresolved reference

External reference

10.1093/bioinformatics/btt627

10.1093/bioinformatics/btt627 · External reference

10.1002/pro.3978

10.1002/pro.3978 · External reference

10.1101/2021.06.16.448102

10.1101/2021.06.16.448102 · External reference

10.1021/acs.jmedchem.2c01438

10.1021/acs.jmedchem.2c01438 · External reference

10.1016/j.cell.2018.01.006

10.1016/j.cell.2018.01.006 · External reference

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non–Small Cell Lung Cancer

10.1158/0008-5472.can-25-0600 · 2026 · External reference

10.1172/jci164413

10.1172/jci164413 · External reference

10.1038/s41467-024-51828-2

10.1038/s41467-024-51828-2 · External reference

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

10.1038/s41698-022-00337-w · 2022 · External reference

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

10.1038/s41698-021-00181-4 · 2021 · External reference

Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model

10.1016/j.jtho.2022.12.003 · 2023 · External reference